Saturday, 31 October 2026European Markets

ENDÚR Stock Bullish By 33% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of ENDÚR (Oslo Børs Benchmark Index_GI: ENDUR.OL) jumped by a staggering 33.82% in 21 sessions from kr32.5 to kr43.49 at 16:26 EST on Tuesday, after three consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI is rising 1% to kr1,176.93, following the last session's upward trend.

About ENDÚR

Endúr ASA operates as a supplier of construction and maintenance projects, services, and solutions for marine infrastructure businesses in Norway and internationally. It operates through Marine infrastructure, Aquaculture Solutions, and Other segments. The company engages in the construction and maintenance of facilities for land-based aquaculture, quays, harbors, dams, bridges, and other specialized concrete and steel projects. It also offers maritime and ship maintenance services. In addition, the company produces concrete barges for the aquaculture industry. The company was formerly known as Bergen Group ASA and changed its name to Endúr ASA in February 2019. Endúr ASA was founded in 2007 and is headquartered in Bergen, Norway.

Earnings Per Share

As for profitability, ENDÚR has a trailing twelve months EPS of kr-1.62.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ENDÚR's stock is considered to be overbought (>=80).

Volume

Today's last reported volume for ENDÚR is 34640 which is 86.91% below its average volume of 166939.

More news about ENDÚR (ENDUR.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com